Independent analysis for European life sciences leaders
Pharma, MedTech, digital health and AI.
Life Sciences Commercial Transformation in Europe
disrupting.healthcare is an independent, practitioner-led publication analysing the commercial shifts reshaping pharma, MedTech and digital health in Europe: operating models, AI, regulation, market access, evidence and execution.
Who writes disrupting.healthcare?
Piotr Wrzosinski is a life sciences commercial transformation leader with more than 20 years of experience across pharma, MedTech and consulting. His career spans BD, Roche, Janssen/J&J, Pfizer, Accenture and IQVIA.
At BD, he is building the commercial operating infrastructure that supports transformation across more than 30 EMEA markets.
disrupting.healthcare is an independent, Europe-focused publication written from an operator’s perspective. Sources are linked, analysis is clearly distinguished from reported fact, and the publication does not accept sponsored placement.
Start Here: Three Core Analyses
Three pieces that define the publication’s point of view on commercial transformation, digital health scale and European market intelligence.
AI-Powered Commercial Operating Models
Digital Health Commercialisation in Europe
European HealthTech Market Map 2026
The Weekly Signal: What Matters in European Life Sciences
A weekly editorial briefing on the regulatory, commercial, scientific and capital-market moves reshaping pharma, MedTech and digital health in Europe. Each issue links to primary sources wherever available, and focuses on what the news changes for operators.
Europe Life Sciences Weekly Signal #45: The Moat Is Moving Beyond the Molecule
Week of 6–12 July 2026 Two British discovery platforms found larger pharmaceutical balance sheets this week. Astex licensed compounds from its breast-cancer discovery programme to Genentech. Myricx Bio, spun out of Imperial College London and the Francis Crick Institute, agreed to be acquired by Novartis for up to $1.5 billion. Both are commercial successes. Together,…
Europe Life Sciences Weekly Signal #44: The Label Is the Strategy
Week of 29 June – 5 July 2026 The headline number this week was a deal figure. Naturally. Life sciences still loves a large cheque almost as much as it loves pretending “strategic optionality” is a strategy. But the real value this week was not created in the deal room. It was created at the…
Europe Life Sciences Weekly Signal #43: The System Is Becoming the Product
Week of 22–28 June 2026 For a long time, life sciences companies could behave as if the product sat at the centre of everything. Develop the asset. Generate the evidence. Secure approval. Build the launch plan. Push adoption. That sequence still exists, of course. But it no longer explains where advantage is created. This week’s…
Explore disrupting.healthcare
Commercialization, AI and digital health, regulation and market access: three lenses on the same question: what makes life sciences innovation work in Europe?
Independent analysis. No sponsored placements. Sources linked.